Search research articles
Contact Us
Filters
Showing results (911-920 of 922) with videos related to
Page
of 93
Sort By:
Journal of Medicinal Chemistry
|
February 12, 2026
Discovery and In Vivo Evaluation of Aryl Ether YAP1/TEAD Inhibitors for the Treatment of Hippo-Driven Malignancies
Brandon A Vara, Jongwon Lim, Casey J Moure, et al.
Journal of Medicinal Chemistry
|
December 2, 2020
Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development
Hexiang Wang, Bo Ren, Ye Liu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
September 7, 2023
Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma
Pingjun Chen, Frank R Rojas, Xin Hu, et al.
Circulation. Cardiovascular Genetics
|
August 27, 2015
DNA Methylation of the Aryl Hydrocarbon Receptor Repressor Associations With Cigarette Smoking and Subclinical Atherosclerosis
Lindsay M Reynolds, Ma Wan, Jingzhong Ding, et al.
Journal of Medicinal Chemistry
|
May 2, 2024
Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2
Yunhang Guo, Hai Xue, Nan Hu, et al.
Nature Communications
|
January 30, 2021
Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas
Xin Hu, Marcos R Estecio, Runzhe Chen, et al.
Journal of Medicinal Chemistry
|
March 13, 2023
Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases
Yunhang Guo, Nan Hu, Ye Liu, et al.
Journal of Medicinal Chemistry
|
April 9, 2026
From KRAS<sup><i>G12D</i></sup> to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design
Xiaoshen Ma, David L Sloman, Timothy J Henderson, et al.
Journal of Medicinal Chemistry
|
August 6, 2019
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
Yunhang Guo, Ye Liu, Nan Hu, et al.
Nature Communications
|
May 12, 2021
Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features
Hitoshi Dejima, Xin Hu, Runzhe Chen, et al.
Page
of 93
Search research articles
Search
Showing results (911-920 of 922) with videos related to
Sort By:
Page
of 93
Journal of Medicinal Chemistry
|
February 12, 2026
Discovery and In Vivo Evaluation of Aryl Ether YAP1/TEAD Inhibitors for the Treatment of Hippo-Driven Malignancies
Brandon A Vara, Jongwon Lim, Casey J Moure, et al.
Journal of Medicinal Chemistry
|
December 2, 2020
Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development
Hexiang Wang, Bo Ren, Ye Liu, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
September 7, 2023
Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma
Pingjun Chen, Frank R Rojas, Xin Hu, et al.
Circulation. Cardiovascular Genetics
|
August 27, 2015
DNA Methylation of the Aryl Hydrocarbon Receptor Repressor Associations With Cigarette Smoking and Subclinical Atherosclerosis
Lindsay M Reynolds, Ma Wan, Jingzhong Ding, et al.
Journal of Medicinal Chemistry
|
May 2, 2024
Discovery of the Clinical Candidate Sonrotoclax (BGB-11417), a Highly Potent and Selective Inhibitor for Both WT and G101V Mutant Bcl-2
Yunhang Guo, Hai Xue, Nan Hu, et al.
Nature Communications
|
January 30, 2021
Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas
Xin Hu, Marcos R Estecio, Runzhe Chen, et al.
Journal of Medicinal Chemistry
|
March 13, 2023
Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases
Yunhang Guo, Nan Hu, Ye Liu, et al.
Journal of Medicinal Chemistry
|
April 9, 2026
From KRAS<sup><i>G12D</i></sup> to Pan-KRAS Inhibitors─A Journey Enabled by Synthetic Innovation and Structure-Based Drug Design
Xiaoshen Ma, David L Sloman, Timothy J Henderson, et al.
Journal of Medicinal Chemistry
|
August 6, 2019
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
Yunhang Guo, Ye Liu, Nan Hu, et al.
Nature Communications
|
May 12, 2021
Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features
Hitoshi Dejima, Xin Hu, Runzhe Chen, et al.
Page
of 93